Thoracic Surgery Department, Institut du Thorax Curie-Montsouris, Institut Mutualiste Montsouris, Paris, France.
Paris 13 University, Sorbonne Paris Cité, Faculty of Medicine SMBH, Bobigny, France.
Eur J Cardiothorac Surg. 2021 Jun 14;59(6):1287-1294. doi: 10.1093/ejcts/ezaa438.
Evaluating morbidity and survival of patients operated on for a second primary non-small-cell lung cancer (NSCLC).
Retrospective collection of data from patients operated on for a second NSCLC between 2009 and 2018.
Fifty-two patients met the inclusion criteria. At the time of second pulmonary resection, the median time between the 2 surgeries was 25 months (5-44.5 months). Patients' median age was 65 years (61-68 years). Median tumour size was 16 mm (10-22 mm). Thoracoscopy was used in 75% of cases. The resection was a pneumonectomy (n = 1), bilobectomy (n = 1), lobectomy (n = 15), segmentectomy (n = 32) or wedge resection (n = 3). The length of stay was 7 days (5-9 days). Mortality was null and morbidity was 36.5%, mainly from grade I-II complications according to the Clavien-Dindo classification. The median follow-up was 28 months (13-50 months). The median overall survival was 67 months (95% confidence interval 60.8-73.1 months). Survival at 5 years and specific survival were 71.1% and 67.7%, respectively.
A second surgical resection of either synchronous or metachronous NSCLC has a morbidity that is not superior to the morbidity of the first operation. The new tumour is usually diagnosed at an early stage. An anatomical sublobar resection is most likely the best compromise. It might also be considered for the first operation when there is a suspicious synchronous lesion that may require surgery at a later stage.
评估因第二原发性非小细胞肺癌(NSCLC)而行手术治疗患者的发病率和生存率。
回顾性收集 2009 年至 2018 年间因第二原发性 NSCLC 而行手术治疗患者的数据。
52 例患者符合纳入标准。在进行第二次肺切除时,两次手术之间的中位时间为 25 个月(5-44.5 个月)。患者的中位年龄为 65 岁(61-68 岁)。中位肿瘤大小为 16mm(10-22mm)。75%的病例采用了胸腔镜手术。切除方式为肺切除术(n=1)、双叶切除术(n=1)、肺叶切除术(n=15)、节段切除术(n=32)或楔形切除术(n=3)。住院时间为 7 天(5-9 天)。无死亡病例,发病率为 36.5%,主要为 Clavien-Dindo 分级的 I-II 级并发症。中位随访时间为 28 个月(13-50 个月)。中位总生存期为 67 个月(95%置信区间为 60.8-73.1 个月)。5 年生存率和特异性生存率分别为 71.1%和 67.7%。
对同步或异时性 NSCLC 进行第二次手术切除的发病率并不高于第一次手术。新肿瘤通常在早期被诊断出来。解剖性亚肺叶切除术可能是最佳的折中方案。对于可能需要在后期手术的可疑同步病变,也可考虑在第一次手术时进行。